Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label spesolimab safety study in fistulising Crohn's disease
2019-001673-93Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of spesolimab in Crohn's disease, sponsored by Boehringer Ingelheim. Primary endpoint: Exposure adjusted rate of patients reporting a treatment emergent adverse event (TEAE). Started Dec 2019; status: completed.
02
Drugs
spesolimab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2019-001673-93.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001673-93.